[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354316-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354316-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-real-world-retrospective-study-of-vitiligo-associated-with-immune-checkpoint-inhibitors-based-on-faers-and-tcga-databases","A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases","","Immune checkpoint inhibitors (ICIs) improve outcomes in advanced malignancies but commonly trigger immune-related adverse events. Vitiligo is a cutaneous immune-related adverse event linked to favorable melanoma prognosis, yet its risk varies across ICI regimens and cancer types. This study retrospectively retrieved ICI-associated vitiligo cases from FAERS (Jan 2015–Sep 2025) and used pharmacovigilance disproportionality methods plus TCGA transcriptomic analyses to evaluate biological mechanisms and onset timing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-real-world-retrospective-study-of-vitiligo-associated-with-immune-checkpoint-inhibitors-based-on-faers-and-tcga-databases/354316/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-real-world-retrospective-study-of-vitiligo-associated-with-immune-checkpoint-inhibitors-based-on-faers-and-tcga-databases/354316.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What datasets were used to assess ICI-associated vitiligo risk and mechanisms?","Question",{"text":63,"@type":64},"The study used FAERS for retrospective case identification and The Cancer Genome Atlas (TCGA) for transcriptomic evaluation of potential biological mechanisms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was risk disproportionality analyzed in the FAERS cases?",{"text":68,"@type":64},"Disproportionality was evaluated using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors influenced vitiligo onset timing in the study?",{"text":72,"@type":64},"Onset timing varied across ICI classes and was significantly influenced by age and geographic factors, with delayed onset in patients aged 65 to 79 and longer time-to-onset reported in Asian patients versus Americans.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354316,1790167237,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","®  \n Observational Study   \nA real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases  \nJingchang Ma, MMa , Zhibo Cai, BMa , Ya Luo, BMa , Xiaojun Li, MMa , Jinyi Li, BMa , Mingjun Hou, MMa , Dingheng Zhu, MMb ,*  \n\n| Abstract\u003Cbr>Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in advanced malignancies but are frequently associated with immune-related adverse events. Vitiligo, a distinctive cutaneous immune-related adverse event, correlates with favorable prognosis in melanoma patients; however, its association with different ICI regimens and occurrence in nonmelanoma cancers remains inadequately characterized. We retrieved ICI-related vitiligo cases from the FDA Adverse Event Reporting System database between January 2015 and September 2025. Disproportionality analysis was performed using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms. The potential biological mechanisms underlying vitiligo induced by ICIs were examined using The Cancer Genome Atlas data. A total of 591 ICI-induced vitiligo cases were identified, wherein 358 (60 .6%) and 177 (29 .9%) were reported as anti-programmed cell death protein 1 and combination therapy. Combination therapy exhibited the highest crude incidence rate (0 .57%), while anti-programmed death-ligand 1 monotherapy showed the lowest (0 .06%) . The ipilimumab–pembrolizumab combination demonstrated the highest reporting odds ratio (97 .2, 95% CI: 58.1–162.4) . Median time-to-onset varied significantly across ICI classes: anti-cytotoxic T-lymphocyte-associated protein 4 monotherapy (33 days), anti-programmed death-ligand 1 (50 days), combination therapy (61 days), and anti-programmed cell death protein 1 (72 days) . Patients aged 65 to 79 years showed significantly delayed onset. Geographic analysis revealed prolonged time-to-onset in Asian patients versus Americans. Pan-cancer transcriptomic analysis demonstrated correlations between ICI-induced vitiligo and melanocyte development, innate immunity, and mitochondrial function. ICI-induced vitiligo exhibits significant heterogeneity in risk across treatment strategies, with combination therapy and anti-cytotoxic T-lymphocyte-associated protein 4 strategies conferring higher relative risks. Onset timing is substantially influenced by age and geographic factors. Integration of pharmacovigilance and transcriptomic data implicates coordinated effects of melanocyte-lineage antigens, innate immune and mitochondrial function pathways in vitiligo pathogenesis. This study aimed to systematically characterize the risk profile, onset timing, and potential biological mechanisms of ICI-induced vitiligo across different treatment strategies and cancer types.\u003Cbr>Abbreviations: CTLA-4 = cytotoxic T-lymphocyte-associated protein 4, FAERS = FDA adverse event reporting system, ICI = immune checkpoint inhibitor, IQR = interquartile range, irAE = immune-related adverse event, PD-1 = programmed cell death protein 1, PD-L1 = programmed death-ligand 1, ROR = reporting odds ratio, TCGA = The Cancer Genome Atlas, TLR = toll-like receptor, TTO = time-to-onset. |\n| --- |\n| Keywords: FAERS, immune checkpoint inhibitors, pharmacovigilance, vitiligo |\n\n1. Introduction  \nImmune checkpoint inhibitors (ICIs), encompassing monoclonal antibodies targeting programmed cell death protein 1 (PD-1), its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have fundamentally transformed the therapeutic  \nlandscape for advanced malignancies. [1,2] By reinvigorating antitumor T-cell responses, these agents achieve durable clinical benefit in a subset of patients across multiple cancer types. However, the augmented immune activation frequently leads toa spectrum of immune-related adverse events (irAEs), which can  \nThe authors have no funding and conflict of interest to disclose. Th","cbCaid7sa0tob9TV","https://ap.wps.com/l/cbCaid7sa0tob9TV","pdf",1399540,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What datasets were used to assess ICI-associated vitiligo risk and mechanisms?\",\"answer\":\"The study used FAERS for retrospective case identification and The Cancer Genome Atlas (TCGA) for transcriptomic evaluation of potential biological mechanisms.\"},{\"question\":\"How was risk disproportionality analyzed in the FAERS cases?\",\"answer\":\"Disproportionality was evaluated using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms.\"},{\"question\":\"What factors influenced vitiligo onset timing in the study?\",\"answer\":\"Onset timing varied across ICI classes and was significantly influenced by age and geographic factors, with delayed onset in patients aged 65 to 79 and longer time-to-onset reported in Asian patients versus Americans.\"}]","A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases | PDF",1790110072,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e985a3893e42763ae27199008c8a2890.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6000f4a12415a2df33888f06bd134ae5.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70a9094eb7ee8f46ab6441ed6107ad5e.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2faad24017d0210d925035a7fc80cf1.webp",980,1306]